PRRT Kidney and Blood Toxicity: Lu-177 Shows Better Tumor Control Than Y-90 in 448 NET Patients
In 448 neuroendocrine tumor patients, PRRT with ¹⁷⁷Lu-DOTATATE showed similar renal toxicity but more hematological effects compared to ⁹⁰Y-DOTATOC, while achieving significantly longer progression-free survival.
Quick Facts
What This Study Found
Among 448 NET patients, ¹⁷⁷Lu-DOTATATE (n=335) showed no significant renal toxicity difference from ⁹⁰Y-DOTATOC (n=113) but caused more hematological effects. ¹⁷⁷Lu-DOTATATE was associated with significantly longer PFS (HR 0.47, P=0.004) but no OS difference.
Key Numbers
448 patients across two US centers. Both 177Lu-DOTATATE and 90Y-DOTATOC forms of PRRT analyzed. Kidney and blood toxicity tracked over treatment course.
How They Did This
Retrospective cohort of 448 NET patients (335 ¹⁷⁷Lu-DOTATATE, 113 ⁹⁰Y-DOTATOC). Renal function tracked via creatinine, BUN, eGFR. Hematological function via WBC, platelets, hemoglobin. Piecewise linear mixed-effect models for longitudinal data. Cox proportional hazard regression for OS and PFS.
Why This Research Matters
PRRT is a mainstay of neuroendocrine tumor treatment, and choosing between ¹⁷⁷Lu and ⁹⁰Y agents involves balancing efficacy against toxicity. This large real-world comparison provides evidence that ¹⁷⁷Lu-DOTATATE offers superior tumor control with manageable side effects.
The Bigger Picture
PRRT represents one of the most successful applications of peptide-based targeted therapy in oncology. As more radiopharmaceuticals enter development, understanding the toxicity-efficacy tradeoff of different radioligands helps optimize treatment selection and monitoring for cancer patients.
What This Study Doesn't Tell Us
Retrospective design with potential selection bias. The two treatment groups may differ in baseline characteristics. Long-term renal effects beyond the follow-up period weren't captured. The study doesn't account for prior or concurrent therapies.
Questions This Raises
- ?Would combining both agents sequentially or in tandem improve outcomes while managing toxicity?
- ?What patient characteristics predict hematological toxicity from ¹⁷⁷Lu-DOTATATE?
- ?Does the PFS advantage of ¹⁷⁷Lu-DOTATATE eventually translate to improved overall survival with longer follow-up?
Trust & Context
- Key Stat:
- HR 0.47 for PFS ¹⁷⁷Lu-DOTATATE nearly doubled progression-free survival compared to ⁹⁰Y-DOTATOC in 448 neuroendocrine tumor patients
- Evidence Grade:
- Moderate evidence from a large retrospective cohort (448 patients). While the sample size is substantial, the non-randomized design limits causal conclusions.
- Study Age:
- Published in 2024; reflects current clinical experience with PRRT in neuroendocrine tumors.
- Original Title:
- Peptide Receptor Radionuclide Therapy and clinical associations with renal and hematological toxicities and survival in patients with neuroendocrine tumors: an analysis from two U.S. medical centers.
- Published In:
- Journal of cancer research and clinical oncology, 150(11), 485 (2024)
- Authors:
- Xu, Tao(3), Dillon, Joseph S(3), Maluccio, Mary A, Quelle, Dawn E, Nash, Sarah H, Cho, Hyunkeun, Limbach, Kristen E, Skill, Nicholas J, Bren-Mattison, Yvette, O'Rorke, Michael A
- Database ID:
- RPEP-09569
Evidence Hierarchy
Frequently Asked Questions
What is PRRT and how does it work?
Peptide Receptor Radionuclide Therapy uses peptides (like DOTATATE or DOTATOC) that specifically bind to receptors found on neuroendocrine tumor cells. These peptides are attached to radioactive atoms that deliver targeted radiation directly to the tumor while sparing most normal tissue.
Should I be worried about kidney damage from PRRT?
This study found that both PRRT agents had similar kidney effects, and renal toxicity was not a significant differentiator. However, kidney function should be monitored during treatment. The more relevant concern is blood count changes (lower white cells, platelets, hemoglobin) which were more common with ¹⁷⁷Lu-DOTATATE.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09569APA
Xu, Tao; Dillon, Joseph S; Maluccio, Mary A; Quelle, Dawn E; Nash, Sarah H; Cho, Hyunkeun; Limbach, Kristen E; Skill, Nicholas J; Bren-Mattison, Yvette; O'Rorke, Michael A. (2024). Peptide Receptor Radionuclide Therapy and clinical associations with renal and hematological toxicities and survival in patients with neuroendocrine tumors: an analysis from two U.S. medical centers.. Journal of cancer research and clinical oncology, 150(11), 485. https://doi.org/10.1007/s00432-024-06020-w
MLA
Xu, Tao, et al. "Peptide Receptor Radionuclide Therapy and clinical associations with renal and hematological toxicities and survival in patients with neuroendocrine tumors: an analysis from two U.S. medical centers.." Journal of cancer research and clinical oncology, 2024. https://doi.org/10.1007/s00432-024-06020-w
RethinkPeptides
RethinkPeptides Research Database. "Peptide Receptor Radionuclide Therapy and clinical associati..." RPEP-09569. Retrieved from https://rethinkpeptides.com/research/xu-2024-peptide-receptor-radionuclide-therapy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.